



(11) **EP 2 965 763 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
15.08.2018 Bulletin 2018/33

(45) Date of publication and mention
of the grant of the patent:
06.06.2018 Bulletin 2018/23

(21) Application number: **15166498.4**

(22) Date of filing: **12.04.2010**

(51) Int Cl.:
A61K 35/74 ^(2015.01) **G01N 33/53** ^(2006.01)
A61K 31/436 ^(2006.01) **A61K 31/352** ^(2006.01)
A61K 31/047 ^(2006.01) **A61K 31/01** ^(2006.01)
A61K 36/45 ^(2006.01) **A61K 36/87** ^(2006.01)
A61K 33/06 ^(2006.01) **A61K 31/26** ^(2006.01)
A61K 31/105 ^(2006.01) **A61K 31/155** ^(2006.01)
A61K 31/4375 ^(2006.01) **A61K 38/22** ^(2006.01)
A61K 31/573 ^(2006.01) **A61K 31/4709** ^(2006.01)
A61K 31/375 ^(2006.01) **A61K 31/355** ^(2006.01)
A61K 31/015 ^(2006.01) **A61K 31/385** ^(2006.01)
A61K 31/122 ^(2006.01)

(54) **ANTI-AGING AGENTS**
ANTI-AGING-MITTEL
AGENTS ANTI-VIEILLISSEMENT

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR

(30) Priority: **10.04.2009 US 168335 P**
10.04.2009 US 168311 P

(43) Date of publication of application:
13.01.2016 Bulletin 2016/02

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
10762568.3 / 2 416 792

(73) Proprietor: **Qi, Haiyan**
Dayton, NJ 10980 (US)

(72) Inventor: **Qi, Haiyan**
Dayton, NJ 10980 (US)

(74) Representative: **Schlief, Thomas P.**
Canzler & Bergmeier
Patentanwlte Partnerschaft mbB
Friedrich-Ebert-Strae 84
85055 Ingolstadt (DE)

(56) References cited:
EP-A1- 0 532 862 WO-A1-2008/109163
WO-A2-2008/022256 US-A1- 2008 181 927

- **TSANG CHI KWAN ET AL: "Targeting mammalian target of rapamycin (mTOR) for health and diseases", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 12, no. 3-4, 1 February 2007 (2007-02-01), pages 112-124, XP002519471, ISSN: 1359-6446, DOI: 10.1016/J.DRUDIS.2006.12.008 [retrieved on 2006-12-15]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).